SV

Street Verdict

Analyst Scorecard

LUPIN · NSE

Lupin Limited

₹2,014

+0.76% (+₹15.2)

Prev. close

₹1,998.8

Volume

6,30,830

Delivery %

59.7%

As of

20 Nov 2026

Price history

₹2,014-₹218 (-9.77%) · 3M
18 Aug 2026 → 20 Nov 2026
1,9502,0002,0502,1002,1502,20018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 12 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Lupin Limited

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Ms. Vinita D. Gupta

Headquarters

Mumbai

Employees

26,021

Website

lupin.com

Key stats

Market cap

₹90,534.27 Cr

P/E ratio (TTM)

16.5

Dividend yield

0.89%

EPS (TTM)

₹120.29

Beta (1Y · daily vs NIFTY 50)

0.52

Beta (5Y · monthly vs NIFTY 50)

0.82

Shares float

24.21 Cr

EPS · quarter ended Jun 2026

₹30.89

Financial Performance

01 · Financials

-50000 Cr0 Cr50000 Cr₹-10%0%10%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

-1000100200₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

05101520₹-50%0%50%100%03 Aug 2027 Jul 2114 Jul 2214 Jul 2316 Jul 2425 Jul 2517 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-20%0%20%40%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr10000 Cr20000 Cr30000 Cr40000 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr10000 Cr20000 Cr30000 Cr40000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr2500 Cr5000 Cr7500 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹15,162.96 Cr₹16,405.48 Cr₹16,641.66 Cr₹20,010.82 Cr₹22,707.90 Cr₹27,958.03 Cr
EBITDA
₹2,703.17 Cr₹428.91 Cr₹1,871.48 Cr₹3,898.12 Cr₹5,479.13 Cr₹8,682.54 Cr
₹1,216.53 Cr₹-1,528.04 Cr₹430.08 Cr₹1,914.48 Cr₹3,281.62 Cr₹5,332.84 Cr
Diluted EPS
₹26.97₹-33.65₹9.41₹41.87₹71.69₹116.44

Net income for Mar 2022 could not be checked against the company's own annual report: this page shows ₹-1,528.04 Cr while the annual report gives ₹-1,509.36 Cr (1.2% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹-269.78 Cr) is left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹23,430.00 Cr₹21,651.00 Cr₹22,800.00 Cr₹23,751.00 Cr₹28,978.00 Cr₹38,146.00 Cr
—₹4,158.38 Cr₹4,541.52 Cr₹2,921.77 Cr₹5,447.77 Cr₹6,616.18 Cr
Stockholders' equity
₹13,803.00 Cr₹12,153.00 Cr₹12,465.00 Cr₹14,290.00 Cr₹17,203.00 Cr₹22,448.00 Cr

Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,239.38 Cr₹1,082.38 Cr₹1,897.24 Cr₹3,648.36 Cr₹2,999.94 Cr₹7,334.50 Cr
Investing cash flow
₹-657.20 Cr₹577.16 Cr₹-1,286.77 Cr₹-1,712.20 Cr₹-4,171.89 Cr₹-3,864.59 Cr
₹-1,885.00 Cr₹-1,572.00 Cr₹-337.00 Cr₹-2,184.00 Cr₹1,732.00 Cr₹-846.00 Cr
Capital expenditure
₹-678.00 Cr₹-905.00 Cr₹-1,500.00 Cr₹-929.00 Cr₹-1,682.00 Cr₹-2,055.00 Cr
End cash position
₹920.63 Cr₹991.37 Cr₹1,264.59 Cr₹983.76 Cr₹1,543.69 Cr₹4,167.73 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25–Sep 25(2Q)Dec 25Mar 26Jun 26
Promoter46.83%46.81%46.78%47.10%47.11%47.10%47.08%47.07%47.06%47.04%47.01%46.98%46.96%46.95%46.92%46.90%46.89%46.86%46.85%
Public53.15%53.18%53.22%52.90%52.89%52.90%52.92%52.93%52.94%52.96%52.99%53.02%53.04%53.05%53.08%53.10%53.11%53.14%53.15%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Lupin Limited₹92,244.53 Cr₹2,008.616.74.1123.8%0.29+23.9%+0.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

LUPIN

Lupin: Nomura raises target price to Rs 2,780, sees nearly 40% upside as valuations turn attractive

Moneycontrol.com · 5 days ago

LUPIN

Zydus Lifesciences Share Price: 25.7% CAGR vs Lupin

Univest · 12 days ago